-
2 months ago | 
hcplive.com | Tim Smith |Adelaide A. Hebert
The December 2024 US Food and Drug Administration (FDA) approval announced by Organon for tapinarof (Vtama) cream 1% expanded the drug’s indicated age range, with patients diagnosed with atopic dermatitis aged 2 years and older now approved to receive the medication.1,2 In a previous interview, the FDA approval of this aryl hydrocarbon receptor agonist and the ADORING phase 3 clinical trial program leading to the approval were discussed between the HCPLive editorial team and ADORING...
-
2 months ago | 
hcplive.com | Adelaide A. Hebert |Tim Smith
Few disease states have seen the same level of advancement in recent years as atopic dermatitis, with notable breakthroughs, such as the December 16, 2024, US Food and Drug Administration (FDA) approval of tapinarof cream 1% (Vtama).1Tapinarof is an aryl hydrocarbon receptor agonist and its approval expands the range of available treatments for atopic dermatitis, 1 of the most prevalent dermatological disorders, providing a new option for patients managing this widespread condition.
-
Jun 5, 2024 | 
digitalcommons.library.tmc.edu | Neal Bhatia |Adelaide A. Hebert |Del Rosso
Home > UTHealth > McGovern Medical School > Journal Articles > 1011 Journal of Clinical and Aesthetics Dermatology
DOWNLOADS COinS
-
Feb 27, 2024 | 
hcplive.com | Adelaide A. Hebert
Psoriasis (PsO) is a chronic, multisystem disorder that occurs in approximately 1% of children. Most frequently, PsO initially presents during adolescence; however, about one-third of patients develop the disease during childhood. PsO is associated with numerous comorbidities, including psoriatic arthritis (PsA).1 The increased frequency of obesity among the pediatric population may account for the growing incidence and prevalence of childhood PsO.
-
Jan 26, 2024 | 
dermatologytimes.com | Raj Chovatiya |Adelaide A. Hebert
This is a video synopsis/summary of a panel discussion involving Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD. In summary, the discussion revolves around the positive outcomes observed in the clinical trials, ADORING 1 and ADORING 2 of a nonsteroidal topical therapy for moderate to severe atopic dermatitis.
-
Jan 26, 2024 | 
dermatologytimes.com | Raj Chovatiya |Adelaide A. Hebert
This is a video synopsis/summary of a panel discussion involving Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD. The speaker addresses the crucial aspect of tolerability and safety in relation to tapinarof during clinical trials for atopic dermatitis. Emphasizing the significance of patient concerns about tolerability and safety, the speaker discusses the low incidence of treatment-related adverse events.
-
Jan 19, 2024 | 
dermatologytimes.com | Raj Chovatiya |Adelaide A. Hebert
This is a video synopsis/summary of a panel discussion involving Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD. In a recent discussion about a therapeutic approach for managing itch in patients with atopic dermatitis, the focus was on presenting data in a way that's understandable to both healthcare providers and patients.
-
Jan 19, 2024 | 
dermatologytimes.com | Raj Chovatiya |Adelaide A. Hebert
This is a video synopsis/summary of a panel discussion involving Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD. The speaker discusses efficacy results of clinical trials, specifically focusing on the EASI (eczema area and severity index) 75 endpoint for patients using a tapinarof. In both ADORING 1 and ADORING 2 trials, the speaker notes similar outcomes with approximately 55.8% and 59.1% of patients achieving EASI75, respectively, after 8 weeks of once-daily application.
-
Jan 12, 2024 | 
dermatologytimes.com | Raj Chovatiya |Adelaide A. Hebert
This is a video synopsis/summary of a panel discussion involving Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD. The transcript discusses data related to the rapid reduction of itching in patients with atopic dermatitis using tapinarof. The primary focus is on the speed and effectiveness of itch relief, challenging the traditional belief that non-steroidal treatments are less effective than steroids.
-
Jan 12, 2024 | 
dermatologytimes.com | Raj Chovatiya |Adelaide A. Hebert
This is a video synopsis/summary of a panel discussion involving Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD. The transcript discusses key aspects of a clinical trial, focusing on the design, patient demographics, and safety considerations for tapinarof in the treatment of atopic dermatitis. The limitations of assessing itch severity in younger individuals are acknowledged, but the speaker notes that data from older children, less than 12 years old, is reasonably reliable.
